OTCPK:EKDH.F

Stock Analysis Report

Executive Summary

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internationally.

Snowflake

Fundamentals

Flawless balance sheet with proven track record.

Share Price & News

How has EKF Diagnostics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

EKDH.F

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

n/a

EKDH.F

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: Insufficient data to determine how EKDH.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how EKDH.F performed against the US Market.


Shareholder returns

EKDH.FIndustryMarket
7 Day0%3.2%3.4%
30 Day0%-1.8%-1.0%
90 Dayn/a-0.4%-0.4%
1 Yearn/a10.9%10.0%7.7%5.4%
3 Year94.6%94.6%69.9%64.8%46.2%36.8%
5 Yearn/a128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is EKF Diagnostics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is EKF Diagnostics Holdings undervalued compared to its fair value and its price relative to the market?

14.02x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: EKDH.F ($0.36) is trading above our estimate of fair value ($0.17)

Significantly Undervalued: EKDH.F is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: EKDH.F is good value based on its PE Ratio (14x) compared to the Medical Equipment industry average (40.6x).

PE vs Market: EKDH.F is good value based on its PE Ratio (14x) compared to the US market (17.7x).


Price to Earnings Growth Ratio

Low PEG Ratio: EKDH.F's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: EKDH.F is good value based on its PB Ratio (2.3x) compared to the US Medical Equipment industry average (3.6x).


Next Steps

Future Growth

How is EKF Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

-106.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EKDH.F's earnings are forecast to decline over the next 3 years (-106.4% per year).

Earnings vs Market: EKDH.F's earnings are forecast to decline over the next 3 years (-106.4% per year).

High Growth Earnings: EKDH.F's earnings are forecast to decline over the next 3 years.

Revenue vs Market: EKDH.F's revenue (4.7% per year) is forecast to grow slower than the US market (7.3% per year).

High Growth Revenue: EKDH.F's revenue (4.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if EKDH.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has EKF Diagnostics Holdings performed over the past 5 years?

51.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: EKDH.F has become profitable over the past 5 years, growing earnings by 51.7% per year.

Accelerating Growth: EKDH.F's earnings growth over the past year (195%) exceeds its 5-year average (51.7% per year).

Earnings vs Industry: EKDH.F earnings growth over the past year (195%) exceeded the Medical Equipment industry 28.2%.


Return on Equity

High ROE: EKDH.F's Return on Equity (16.4%) is considered low.


Return on Assets

ROA vs Industry: EKDH.F has a higher Return on Assets than the Medical Equipment industry average last year.


Return on Capital Employed

ROCE Improving: EKDH.F's Return on Capital Employed has declined over the past 3 years.


Next Steps

Financial Health

How is EKF Diagnostics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: EKDH.F's short term assets (£27.7M) exceeds its short term liabilities (£15.3M)

Long Term Liabilities: EKDH.F's short term assets (27.7M) exceeds its long term liabilities (4.3M)


Debt to Equity History and Analysis

Debt Level: EKDH.F's debt to equity ratio (1.5%) is considered satisfactory

Reducing Debt: EKDH.F's debt to equity ratio has reduced from 6% to 1.5% over the past 5 years.

Debt Coverage: EKDH.F's debt is well covered by operating cash flow (888.7%).

Interest Coverage: EKDH.F earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: EKDH.F has a high level of physical assets or inventory.

Debt Coverage by Assets: EKDH.F's debt is covered by short term assets (assets are 28.572600x debt).


Next Steps

Dividend

What is EKF Diagnostics Holdings's current dividend yield, its reliability and sustainability?

3.02%

Forecast Dividend Yield


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Years3.0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate EKDH.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate EKDH.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if EKDH.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EKDH.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EKDH.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of EKF Diagnostics Holdings's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average board tenure


CEO

Julian Baines (54yo)

0yrs

Tenure

UK£346,000

Compensation

Mr. Julian Huw Baines, MBE, is Non-Executive Chairman of Renalytix AI plc. Mr. Baines serves as the Chief Executive Officer and Executive Director of EKF Diagnostics Holdings plc. Mr. Baines serves as a Di ...


CEO Compensation Analysis

Compensation vs. Market: Julian's total compensation ($USD440.86K) is below average for companies of similar size in the US market ($USD1.16M).

Compensation vs Earnings: Julian's compensation has been consistent with company performance over the past year.


Board Age and Tenure

3.5yrs

Average Tenure

62yo

Average Age

Experienced Board: EKDH.F's board of directors are considered experienced (3.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£62,98828 May 19
Christopher Mills
EntityIndividual
Role
Chairman of the Board
Non-Executive Chairman
Shares150,000
Max PriceUK£0.42
SellUK£167,46028 May 19
Adam Reynolds
EntityIndividual
Role
Lead Director
Senior Independent Director
Shares400,000
Max PriceUK£0.42
SellUK£110,29707 Dec 18
Harwood Capital LLP
EntityCompany
Shares320,539
Max PriceUK£0.34
SellUK£59,01822 Nov 18
Harwood Capital LLP
EntityCompany
Shares170,954
Max PriceUK£0.35
SellUK£172,79921 Nov 18
Harwood Capital LLP
EntityCompany
Shares491,493
Max PriceUK£0.35
SellUK£17,96020 Nov 18
Harwood Capital LLP
EntityCompany
Shares53,423
Max PriceUK£0.34
SellUK£442,65809 Nov 18
Adam Reynolds
EntityIndividual
Role
Lead Director
Senior Independent Director
Shares1,250,000
Max PriceUK£0.35

Ownership Breakdown


Management Team

  • Julian Baines (54yo)

    CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£346.00k
  • Andrew Webb

    Chief Executive Officer of Ekf Molecular

    • Tenure: 6.6yrs
  • Richard Evans (62yo)

    COO, Finance Director & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£283.00k
  • Salim Hamir

    Company Secretary

    • Tenure: 3.6yrs

Board Members

  • Julian Baines (54yo)

    CEO & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£346.00k
  • Chris Mills (65yo)

    Non-Executive Chairman

    • Tenure: 3.5yrs
    • Compensation: UK£25.00k
  • Carl Contadini (71yo)

    Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: UK£25.00k
  • Adam Reynolds (56yo)

    Senior Independent Director

    • Tenure: 0yrs
    • Compensation: UK£30.00k
  • Richard Evans (62yo)

    COO, Finance Director & Executive Director

    • Tenure: 0yrs
    • Compensation: UK£283.00k

Company Information

EKF Diagnostics Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: EKF Diagnostics Holdings plc
  • Ticker: EKDH.F
  • Exchange: OTCPK
  • Founded: 1990
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: UK£150.532m
  • Listing Market Cap: UK£191.802m
  • Shares outstanding: 454.09m
  • Website: https://www.ekfdiagnostics.com

Number of Employees


Location

  • EKF Diagnostics Holdings plc
  • Avon House
  • 19 Stanwell Road
  • Cardiff
  • South Glamorgan
  • CF64 2EZ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EKFAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJun 2002
EKDH.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2002

Biography

EKF Diagnostics Holdings plc designs, develops, manufactures, and sells diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Africa, Asia, and internatio ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:02
End of Day Share Price2019/09/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.